Tag: HMG-CoA reductase inhibitors (Page 3)
Analysis of atorvastatin-treated patients receiving concomitant antihypertensive therapy, hypoglycemic agents or estrogen replacement therapy showed no clinically significant adverse interactions. The following drug interactions are reported in the product monograph for ator-vastatin. Coadministration of atorvastatin with colestipol resulted in lower plasma concentrations of atorvastatin; however, LDL-C reduction was greater with the combination than with either […]
There were no clinically important elevations in creatine phosphokinase associated with atorvastatin in the clinical trials . Myalgia was reported in 1% of patients treated with atorvastatin. This incidence was similar to that reported for patients on placebo or those treated with the other HMG-CoA reductase inhibitors. No cases of myoglobinuria or acute renal failure […]
In the placebo controlled clinical trials, the general incidence of adverse events in patients receiving atorvastatin was not significantly different from that seen in patients receiving placebo (Table 7) . Analysis of data from these studies showed no consistent dose-related increase in frequency or type of adverse event.
Safety data for atorvastatin have been reported for 4271 patients: 2502 patients from an integrated safety database from 21 completed clinical trials and 1769 patients from 23 ongoing studies, with the latter data contributing additional analyses for liver and muscle safety . Patients from the integrated safety database received atorvastatin for a total of 1845 […]
In addition, analysis of pooled data from several studies involving over 2000 patients with mild to moderate hypercholesterolemia showed that over 70% of patients had at least a 30% reduction in LDL-C levels with the 10 mg/day dose and that 95% of patients achieved 15% or greater lowering of LDL-C with this dose (unpublished data, […]
The recommended dose of atorvastatin is 10 mg/day, at which most patients are expected to achieve and maintain target cholesterol levels . The dose range is 10 to 40 mg/day for most patients with primary hypercholesterolemia and combined (mixed) hyperlipidemia (Fredrickson types IIa and IIb). The maximum dose is 80 mg/day, which benefits patients with […]
All HMG-CoA reductase inhibitors work by competitively inhibiting the rate-limiting step in cholesterol synthesis, the conversion of HMG-CoA to mevalonate . As a result, cholesterol formation is inhibited, and intracellular cholesterol levels decrease, especially in the liver, which requires cholesterol as a substrate for bile acid synthesis. To overcome this shortfall, hepatocytes express a greater […]